Phase IIa randomized placebo-controlled clinical trial to evaluate the efficacy of bromhexine in combination with standard therapy in the early treatment of COVID-19 in primary care patients DOI Open Access
David Ramírez, Romina Rojas,

Humberto Fierro

и другие.

Опубликована: Июнь 30, 2024

The continuous appearance of SARS-CoV-2 variants with both increased transmission and immune evading potential, in addition to the reluctance some populations be vaccinated, supports search for alternative treatments protect against viral infection consequences. Bromhexine is a well-known, over-the counter, expectorant which have garnered interest potential prevention treatment COVID-19. Here, we report results placebo-controlled randomized clinical trial efficacy oral bromhexine was tested outpatients mild moderate symptomatic Adult patients diagnosed active were randomly assigned (1:1) receive or placebo, groups also receiving standard care. primary endpoint load reduction (day 4 vs. baseline), while reductions series COVID-19 symptoms considered as secondary endpoints. No differences at different times after initiation observed. In addition, no between detected most evaluated. Remarkably, significant decrease percentage cough observed days 5-7 group, an effect that not apparent group placebo. Since coughing one main forms SARS-CoV-2, this might highly beneficial particularly living crowded, poorly ventilated, confined environments.

Язык: Английский

Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein DOI Creative Commons

Xiafei Wei,

Yuzheng Zhou, Xiaotong Shen

и другие.

Acta Pharmaceutica Sinica B, Год журнала: 2024, Номер 14(6), С. 2505 - 2519

Опубликована: Март 12, 2024

The nucleocapsid protein (NP) plays a crucial role in SARS-CoV-2 replication and is the most abundant structural with long half-life. Despite its vital severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assembly host inflammatory response, it remains an unexplored target for drug development. In this study, we identified small-molecule compound (ciclopirox) that promotes NP degradation using FDA-approved library drug-screening cell model. Ciclopirox significantly inhibited both vitro vivo by inducing degradation. induced abnormal aggregation through indirect interaction, leading to formation of condensates higher viscosity lower mobility. These were subsequently degraded via autophagy-lysosomal pathway, ultimately resulting shortened half-life reduced expression. Our results suggest potential target, ciclopirox holds substantial promise further development combat replication.

Язык: Английский

Процитировано

5
Sensitive dual-channel lateral flow immunoassay tagged with high brightness latex microsphere for simultaneous detection of respiratory viral antigens DOI
Tao Dong,

Guangze Sun,

Zhonghuang Yang

и другие.

Chemical Engineering Journal, Год журнала: 2024, Номер 497, С. 154826 - 154826

Опубликована: Авг. 13, 2024

Язык: Английский

Процитировано

4
Efficacy of facial masks against COVID-19 DOI
Aslıhan Candevir

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 793 - 804

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Clinical features and effectiveness of SARS-CoV-2 vaccine in children with omicron infection in a tertiary hospital during the Omicron wave in China, December 2022–January 2023 DOI Creative Commons
Sujie Zheng,

Hao Guo,

Ning Liu

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Фев. 1, 2024

Abstract There are limited data about Omicron infection in children China. Here, we evaluated the fatality rates, clinical features and efficacy of SARS-CoV-2 vaccine with a tertiary hospital during first wave caused by China, December 2022-January 2023.We used week as statistical unit, positive rate NAT was 0.03% from 1 to 7, before Zero-COVID strategy relaxed. Following repeal policy, rose 8.3% week, peaked at 85.2% third then steadily fell.The (90.4%) following termination policy.43.6% (232/532) 532 pediatric patients received vaccinations, majority (95.3%, 221/232) receiving two doses remainder one.532 641 who tested for were seen outpatient clinic. Eventually, 51 admitted hospitals. Overall, symptoms mild, severe disease low, whereas vaccination had favorable effect on lowering risk illness children.

Язык: Английский

Процитировано

0
Evaluation of the Potential of Urinary Volatilomic Patterns of COVID-19 Patients Infected With SARS-CoV-2 for Disease Diagnosis. An Exploratory Study DOI Open Access
Giulia Riccio, Joana Neto, Cristina V. Berenguer

и другие.

Опубликована: Апрель 4, 2024

To assess if SARS-CoV-2 infection induces changes in the urinary volatilomic fingerprint able to be used non-invasive COVID-19 diagnosis and management, urine samples of infected patients (62), recovered (30), non-infected individuals (41) were analysed using solid-phase microextraction technique headspace mode, combined with gas chromatography hyphenated mass spectrometry (HS-SPME/GC-MS). In total, 101 volatile organic metabolites (VOMs) from 13 chemical families identified, being terpenes, phenolic compounds, norisoprenoids, ketones most represented groups. Overall, a decrease levels terpenes compounds was observed control group, whereas norisoprenoids showed significant increase. turn, remarkable increase noticed milder alcohols, furanic, sulfur recovery group than group. Multivariate statistical analysis identified sets VOMs potential constitute signatures for development progression. These are composed D-carvone, 3-methoxy-5-(trifluoromethyl)aniline (MTA), 1,1,6-trimethyl-dihydronaphthalene (TDN), 2-heptanone, 2,5,5,8a-tetramethyl-1,2,3,5,6,7,8,8-octahydro-1-naphthalenyl ester acetate (TONEA) nonanoic acid, α-terpinene, β-damascenone, α-isophorone, trans-furan linalool recovering disease. This study provides evidence that profile triggered by promising valuable screening and/or diagnostic management tool clinical environment.

Язык: Английский

Процитировано

0
Evaluation the potential of urinary volatilomic patterns of patients infected with SARS-CoV-2 for COVID-19 diagnosis. An exploratory study DOI Open Access
José S. Câmara, Giulia Riccio, Joana Neto

и другие.

Authorea (Authorea), Год журнала: 2024, Номер unknown

Опубликована: Апрель 15, 2024

To assess whether SARS-CoV-2 infection induces changes in the urinary volatilomic fingerprint suitable for non-invasive COVID-19 diagnosis and management, urine samples from infected patients (62), recovered (30), non-infected individuals (41), were analysed using solid-phase microextraction technique headspace mode, combined with gas chromatography hyphenated mass spectrometry (HS-SPME/GC-MS). A total of 101 volatile organic metabolites (VOMs) 13 chemical families characterized, terpenes, phenolic compounds, norisoprenoids, ketones being most represented groups. Overall, levels terpenes compounds decreased control group, whereas those norisoprenoids increased significantly. In turn, a remarkable increase was noticed milder alcohols, furanic, sulfur recovery group than COVID group. Multivariate statistical analysis identified sets VOMs that could constitute signatures development progression. These are composed D-carvone, 3-methoxy-5-(trifluoromethyl)aniline (MTA), 1,1,6-trimethyl-dihydronaphthalene (TDN), 2-heptanone, 2,5,5,8a-tetramethyl-1,2,3,5,6,7,8,8-octahydro-1-naphthalenyl ester acetate (TONEA) nonanoic acid, α-terpinene, β-damascenone, α-isophorone, trans-furan linalool recovering disease. The study reported current article provides evidence profile triggered by promising valuable screening and/or diagnostic management tool clinical environment.

Язык: Английский

Процитировано

0
Phase IIa randomized placebo-controlled clinical trial to evaluate the efficacy of bromhexine in combination with standard therapy in the early treatment of COVID-19 in primary care patients DOI Open Access
David Ramírez, Romina Rojas,

Humberto Fierro

и другие.

Опубликована: Июнь 30, 2024

The continuous appearance of SARS-CoV-2 variants with both increased transmission and immune evading potential, in addition to the reluctance some populations be vaccinated, supports search for alternative treatments protect against viral infection consequences. Bromhexine is a well-known, over-the counter, expectorant which have garnered interest potential prevention treatment COVID-19. Here, we report results placebo-controlled randomized clinical trial efficacy oral bromhexine was tested outpatients mild moderate symptomatic Adult patients diagnosed active were randomly assigned (1:1) receive or placebo, groups also receiving standard care. primary endpoint load reduction (day 4 vs. baseline), while reductions series COVID-19 symptoms considered as secondary endpoints. No differences at different times after initiation observed. In addition, no between detected most evaluated. Remarkably, significant decrease percentage cough observed days 5-7 group, an effect that not apparent group placebo. Since coughing one main forms SARS-CoV-2, this might highly beneficial particularly living crowded, poorly ventilated, confined environments.

Язык: Английский

Процитировано

0